England is at the forefront of the genomics revolution – but NHS patients are unlikely to be the first to benefit.
JP Morgan 2018
Axovant misreports trial results, Lundbeck Alzheimer’s drug fails
Bad week for dementia R&D after Axovant howler and another failed trial
Walmsley has axed 40% of management team in shake-up
A Pfizer consumer buyout won’t detract from pharma business, says GSK chief
Health firms should prepare for Amazon move, says J&J chief